Bristol-Myers Squibb announced new long-term data of Opdivo (nivolumab) in treatment-naïve BRAF wild-type advanced melanoma from CheckMate -066 at the Society for Melanoma Research (SMR) 2015 International Congress.
MRV Research
Prognostic Score Proposed for Patients With Advanced Melanoma Treated With Ipilimumab
Researchers propose a simple prognostic score for survival that consists of 3 risk groups in patients with advanced melanoma treated with ipilimumab using readily available clinical parameters, according to a study published in the European Journal of Cancer.
Study Shows Castle Biosciences’ DecisionDx-UM is Highly Effective at Predicting Metastatic Risk in Patients with Eye Cancer
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced new study results of the Company’s DecisionDx-UM gene expression profile test, verifying that the assay is highly effective at identifying uveal melanoma tumors at high risk of metastasis. The results also confirmed the technical reliability of the test, which successfully classified 97% of uveal melanomas submitted for testing in this case series.
Melanoma’s Genetic Trajectories Are Charted in New Study
An international team of scientists led by UC San Francisco researchers has mapped out the genetic trajectories taken by melanoma as it evolves from early skin lesions, known as precursors, to malignant skin cancer, which can be lethal when it invades other tissues in the body.